Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which proceeds slowly and cannot be directly attributed to hypertension or other cardiovascular disorders.
Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.
Affinia Therapeutics Inc. has nominated AFTX-201 as a development candidate for the treatment of BAG3 dilated cardiomyopathy. The gene therapy, using Affinia’s cardiotropic capsid, is given as a ...